On April 21, 2020, Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around a newly identified class of enzymes to target Parkinson's disease and other age-related disorders, announced that it has closed a Series A financing of $38 million co-led by Sofinnova Partners, a leading European life sciences venture capital firm, and AbbVie Ventures, AbbVie's corporate strategic venture capital arm, with further participation from the Dementia Discovery Fund, Mission Bay Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati represented Nitrome in the transaction.

The financing is intended to support the advancement of Nitrome’s lead program targeting Parkinson’s Disease toward human clinical proof of concept studies and to explore the application of the company’s platform technology in other age-related disorders.

Nitrome has been widely recognized and has won multiple awards including the Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research. Nitrome was also awarded the 2018 AbbVie Golden Ticket, and allocated lab space at the San Francisco incubator MBC BioLabs. Nitrome subsequently won three additional Golden Tickets from MBC BioLabs’ partners.

The Wilson Sonsini team that advised Nitrome Biosciences in the transaction includes Elton Satusky, Brian Appel, Patricia Swen, and Lenka Schvaigerova.

For more information, please see Nitrome Biosciences’ press release.